News & Trends - MedTech & Diagnostics
Medical Technology industry thanks outgoing Health Secretary

MTAA CEO Ian Burgess has today thanked outgoing Department of Health Secretary Glenys Beauchamp PSM for her service to the health industry throughout the course of a long and distinguished career.
“On behalf of the medical technology industry I would like to thank Ms Beauchamp for her dedication and commitment to serving the healthcare industry,” Mr Burgess said today.
“Ms Beauchamp presided over the signing of MTAA’s 2017 Agreement with the Government, which has since delivered the lowest Private Health Insurance premium increases for three years running.
“I congratulate Ms Beauchamp on her significant achievements throughout her career and wish her well into the future,” Mr Burgess said.
Enhance employer branding and industry thought leadership to attract and retain quality employees. Health Industry Hub is the only one-stop-hub connecting your organisation to Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with our unique media solutions.
The recommendation that Professor Brendan Murphy be appointed to the role was also welcomed by Mr Burgess. Professor Murphy is a medical doctor, a health administrator, a company director, and former President of the Australian and New Zealand Society of Nephrology.
“We look forward to working with Professor Murphy to ensure that all Australians have access to the best quality medical devices and care,” Mr Burgess concluded.
Professor Murphy will be the first medical doctor to serve as Secretary of the Federal Department of Health. The last doctor to head health was Dr Gwyn Howells, who held the position of Director General from 1973-1982.
Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.
News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines
Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]
MoreNews & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug
Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]
MoreNews & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban
Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]
MoreNews & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day
As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]
More